RBC disorders 5 Ahmad Mansour, MD.

Slides:



Advertisements
Similar presentations
MYELOPROLIFERATIVE DISEASES By DR. FATIMA AL-QAHTANI CONSULTANT HAEMATOLOGIST.
Advertisements

NEOPLASTIC DISORDERS OF THE BONE MARROW
Myeloproliferative Disorder
Myelodysplastic Syndrome
Inclusion Pediatric and adult patients with suspected congenital primary and secondary erythrocytosis Patients < 20 years with polycythemia vera Exclusion.
Polycythemia Group C: Melanie, Michele, Sarah.
Myeloproliferative Disorders (Neoplasm)II Dr. Ibrahim. A. Adam.
Myeloproliferarive Disorder
Polycythemia Vera (lots of red cells - for real)
WHO CLASSIFICATION OF MYELOID NEOPLASMS 2000  Chronic myeloproliferative disorders (CMPD)  Myelodysplastic / myeloproliferative diseases (MDS/MPD) 
APMG Pathologist, MD FCAP
AM REPORT. The Budd Chiari Syndrome and Polycythemia Vera Ryan Sanford
Morning Report 7/7/2010 Pahresah Roomiany.  Factor V Leiden  Prothrombin gene mutation  Protein C/S deficiency  Antithrombin deficiency  Malignancy.
Essential Thrombocythemia Followed by Acute Leukemia
Polycythemia Victor Politi, M.D., FACP Medical Director, SVCMC, School of Allied Health Professions, Physician Assistant Program.
Myeloproliferative Neoplasms 2015
MLAB Hematology Keri Brophy-Martinez
Differential Diagnosis
MLAB Hematology Keri Brophy-Martinez Unit 23: CHRONIC MYELOPROLIFERATIVE DISORDERS (MPD)
Polycythemia Emmanuel Akuna Lab values. Normal platelet 150, ,000 CELLS/MM 3 Hemoglobin- men g/dl women g/dl Hematocrit.
Differential Diagnosis of Polycythemia Vera. True / Absolute Polycythemia Either a clonal myeloproliferative disorder (polycythemia vera) or a nonclonal.
Ahmad Sh. Silmi Msc Haematology, FIBMS.  The Non-leukaemic Malignant Disorders are originally defined, as an amorphous group of malignant disorders which.
THROMBOTIC COMPLICATIONS IN PATIENTS WITH POLYCYTHEMIA VERA Coordinator: Asist. Univ. Dr. Marcela Candea Authors: Ioana-Violeta Oltean Ioana Barsan Madalina.
Myeloproliferative disorders Dr. Tariq Roshan PPSP Department of Hematology.
Myeloproliferative Disorders (MPD) concepts Neoplastic (clonal) disorders of hemopoietic stem cells Over-production of all cell lines, with usually one.
The Chronic Myeloproliferative Disorders (MPD) A JENABIAN MD.
Myeloproliferative disorders Clonal haematopoeitic disorders Proliferation of one of myeloid lineages –Granulocytic –Erythroid –Megakaryocytic Relatively.
Myeloproliferative Disorders (MPDs)
Red blood Cell Changes and Circulatory problems
Hypercoagulable States: Polycythemia Vera Chris Caulfield AM Report Oct 20, 2009.
About these slides SPEC – Short Presentation in Emerging Concepts
Chicago Medical School
Definition of polycythemia
Myeloproliferative Diseases Mark D. Browning, M.D. Oncology/Hematology Associates February 24, 2016.
Myeloprolifrative disorders Dr.musa Qasim Hussein Assistant professor Consultant physician 29th feb.2016.
Gary Schiller, MD Nothing to disclose Discussion of off-label drug use: not applicable 56 th ASH Annual Meeting Disclosure Statement.
October 2014 Myeloproliferative Neoplasms Angela Fleischman Division of hematology/Oncology.
골수증식 질환 Myeloproliferative disorders (MPD) [ 새로운 분류와 진단 기준 ] 경희의대 종양혈액내과 조 경 삼.
Nada Mohamed Ahmed, MD, MT (ASCP)i. Objectives chronic myeloid leukaemia (CML) Haematopoietic malignancies Polycythemia vera (PV) Idiopathic myelofibrosis.
Myeloprolifrative disorders
Definition of polycythemia
Department of Hematology and Oncology R3 Joonbeom Shin
Myelodysplastic Syndromes Myeloproliferative Disorders
Pediatric polycytemia case presentation
MYELOPROLIFERATIVE DISEASES
Anemia By: Dr Sunita Mittal.
Definition of polycythemia
MYELOPROLIFERATIVE DISORDERS
Polycythemia Vera Bleeding Disorders
POLYCYTHEMIA VERA.
Packed cell volume (PCV) or Haematocrit (HCT)
Assistant Prof. Dr. Nibras Saleam Al-Ammar PhD in Clinical Immunology
Do you have any suggestions? Please contact us!
Erythropoietin (EPO) measurements in patients with various forms of erythrocytosis. When compared with the normal response, polycythemia vera patients.
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Polycythemia Wendy Blount, DVM.
Giovanni Barosi Center for the Study of Myelofibrosis.
Case Study ….
Chronic Leukemia Kristine Krafts, M.D..
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Packed cell volume count (Hematocrit)
Polycythemia Vera: A Comprehensive Review and Clinical Recommendations
Practical Clin Path Polycythemia
Prefibrotisk Myelofibros
Erythropoietin (EPO) Mike Lin.
Leukemia case Maha Areej Faten.
Male patient of 52 years old with a two-year history of fatigue and pruritus of his legs , headache . And visual disturbances . He smoked one pack of.
Polycytemia Dr. Mamlook Elmagraby.
Chronic Leukemia Dr. Noha Noufal.
The Non – Leukemic Myeloproliferative Disorders
Presentation transcript:

RBC disorders 5 Ahmad Mansour, MD

1- Relative polycythemia occurs in the setting of Wilms tumor Dehydration Renal cell carcinoma Polycythemia vera hypoxia

2- All of the following are examples of secondary absolute polycythemia, except: Smokers Renal artery stenosis Polycystic kidney Polycythemia vera High altitude

3- The risk acute myeloid leukemia in polycythemia vera is 2% 10% 30% 50% 70%

4- One of the following is a major criterion for PV High hemoglobin Hypercellular bone marrow Low erythropoietin level High erythropoietin level Endogenous erythroid colony formation in vitro

Polycythemia Polycythemia denotes an abnormally high red cell count, usually with a corresponding increase in the hemoglobin level.

Relative Absolute Primary Secondary

Relative Decrease plasma volume with intaact total RBC mass Dehydration Diarrhea Diuretic therapy

Absolute Increase RBC mass With high EPO (secondary) Low EPO (primary)

Hypoxia Certain neoplasms Generalized Localized Wilms tumor Smoking High altitude High affinity hemoglobins Localized Renal artery stenosis Polycystic kidney disease Certain neoplasms Wilms tumor Renal cell carcinoma Celebellar hemangioma Hepatocellular carcinoma

Polycythemia vera Low EPO Polycythemia vera (PCV) is characterized by increased marrow production of red cells, granulocytes, and platelets (panmyelosis), but it is the increase in red cells (polycythemia) that is responsible for most of the clinical symptoms

Strongly associated with JAK2 mutation Valine-to-phenylalanine substitution at residue 617. Patients are prone to both thrombosis and bleeding. Splenomegaly mild at first severe in spent phase Hypercellular bone marrow.

Late in the disease course, bone marrow fibrosis and significant organomegaly is present.

Clinical features Pruritis Headache dizziness Hyperuricemia and gout increased risk of both major bleeding and thrombotic episodes. Deep venous thrombosis Stroke Myocardial infarction Bowel infarction Budd-chiari syndrome

Epistaxis and bleeding gums Major hemorrhage can occur in ~10% of the patients

Phlebotomy and JAK2 inhibitors Spent phase; fibrosis and splenomegaly 2% might transform to acute myeloid leukemia

Criteria for diagnosis (2major and one minor or the first major with two minor) Major criteria 1. Haemoglobin >18.5 g/dL in men, 16.5 g/dL in women or other evidence of increased red cell volume* 2. Presence of JAK2 V617F or other functionally similar mutation such as JAK2 exon 12 mutation Minor criteria 1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic and megakaryocytic proliferation 2. Serum erythropoietin level below the reference range for normal 3. Endogenous erythroid colony formation in vitro

1- Relative polycythemia occurs in the setting of Wilms tumor Dehydration Renal cell carcinoma Polycythemia vera hypoxia

2- All of the following are examples of secondary absolute polycythemia, except: Smokers Renal artery stenosis Polycystic kidney Polycythemia vera High altitude

3- The risk acute myeloid leukemia in polycythemia vera is 2% 10% 30% 50% 70%

4- One of the following is a major criterion for PV High hemoglobin Hypercellular bone marrow Low erythropoietin level High erythropoietin level Endogenous erythroid colony formation in vitro

THANK YOU